Skip to main content

Advertisement

SpringerLink
Log in

Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK

  • Original Article
  • Published:
Tumor Biology

Abstract

NANOG, a marker of stemness, impacts tumor progression and therapeutic resistance in cancer cells. In human hepatocellular carcinoma (HCC), upregulation of NANOG is associated with metastasis and a low survival rate, while its downregulation results in a lower colony formation rate and enhanced chemosensitivity. Metformin, an agent widely used for diabetes treatment, and AICAR, another AMP-activated protein kinase (AMPK) activator, have been reported to inhibit the growth of several types of cancer. Although inhibitory effects of metformin on NANOG in pancreatic cancer cells and of AICAR in mouse embryonic stem cells have been described, the underlying molecular mechanisms remain uncertain in HCC. In this study, we used the HepG2 cell line and found that metformin/AICAR downregulated NANOG expression with decreased cell viability and enhanced chemosensitivity to 5-fluorouracil (5-FU). Moreover, metformin/AICAR inhibited c-Jun N-terminal kinase (JNK) activity, and blockade of either the JNK MAPK pathway or knockdown of JNK1 gene expression reduced NANOG levels. The upregulation of NANOG and phospho-JNK by basic fibroblast growth factor (bFGF) was abrogated by metformin/AICAR. Additionally, although transient upregulation of NANOG within 2 h of treatment with metformin/AICAR was concordant with both JNK and AMPK activation, increased NANOG expression with activation of JNK was also observed following AMPK inhibition with compound C. Taken together, our data suggest that metformin/AICAR regulate NANOG expression via the JNK MAPK pathway in HepG2 cells independently of AMPK, and that this JNK/NANOG signaling pathway may offer new therapeutic strategies for the treatment of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the erk/jnk-mediated nf-kappab-dependent pathway that reduces upa and mmp-9 expression. Amino Acids. 2014;46:2809–22.

    Article  CAS  PubMed  Google Scholar 

  3. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol. 2014;45:322–32.

    CAS  PubMed  Google Scholar 

  4. Sauer H, Engel S, Milosevic N, Sharifpanah F, Wartenberg M. Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-jun N-terminal kinase. Int J Oncol. 2012;40:501–8.

    CAS  PubMed  Google Scholar 

  5. Jose C, Hebert-Chatelain E, Bellance N, Larendra A, Su M, Nouette-Gaulain K, et al. AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta. 1807;2011:707–18.

    Google Scholar 

  6. Sui X, Xu Y, Yang J, Fang Y, Lou H, Han W, et al. Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation. PLoS ONE. 2014;9:e97781.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wu Y, Qi Y, Liu H, Wang X, Zhu H, Wang Z. AMPK activator AICAR promotes 5-FU-induced apoptosis in gastric cancer cells. Mol Cell Biochem. 2016;411:299–305.

    Article  CAS  PubMed  Google Scholar 

  8. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–20.

    Article  CAS  PubMed  Google Scholar 

  9. Gong S, Li Q, Jeter CR, Fan Q, Tang DG, Liu B. Regulation of NANOG in cancer cells. Mol Carcinog. 2015;54:679–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sun C, Sun L, Jiang K, Gao DM, Kang XN, Wang C, et al. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol. 2013;45:1099–108.

    Article  CAS  PubMed  Google Scholar 

  11. Zhou JJ, Deng XG, He XY, Zhou Y, Yu M, Gao WC, et al. Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression. Int J Oncol. 2014;44:2034–40.

    CAS  PubMed  Google Scholar 

  12. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res. 2012;5:355–64.

    Article  CAS  Google Scholar 

  13. Chae HD, Lee MR, Broxmeyer HE. 5-Aminoimidazole-4-carboxyamide ribonucleoside induces g(1)/s arrest and NANOG downregulation via p53 and enhances erythroid differentiation. Stem Cells. 2012;30:140–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, et al. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/lcn2/twist1 pathway. Hepatology. 2013;58:1349–61.

    Article  CAS  PubMed  Google Scholar 

  15. Risal P, Hwang PH, Yun BS, Yi HK, Cho BH, Jang KY, et al. Hispidin analogue davallialactone attenuates carbon tetrachloride-induced hepatotoxicity in mice. J Nat Prod. 2012;75:1683–9.

    Article  CAS  PubMed  Google Scholar 

  16. Cadena-Herrera D, Esparza-De Lara JE, Ramírez-Ibañez ND, López-Morales CA, Pérez NO, Flores-Ortiz LF, et al. Validation of three viable-cell counting methods: manual, semi-automated, and automated. Biotechnol Reprod. 2015;7:9–16.

    Article  Google Scholar 

  17. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 2005;280:39582–93.

    Article  CAS  PubMed  Google Scholar 

  18. Xu G, Ji W, Su Y, Xu Y, Yan Y, Shen S, et al. Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model. Oncotarget. 2014;5:5029–39.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sukarawan W, Nowwarote N, Kerdpon P, Pavasant P, Osathanon T. Effect of basic fibroblast growth factor on pluripotent marker expression and colony forming unit capacity of stem cells isolated from human exfoliated deciduous teeth. Odontology. 2014;102:160–6.

    Article  CAS  PubMed  Google Scholar 

  20. Meisse D, Van de Casteele M, Beauloye C, Hainault I, Kefas BA, Rider MH, et al. Sustained activation of AMP-activated protein kinase induces c-jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett. 2002;526:38–42.

    Article  CAS  PubMed  Google Scholar 

  21. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma. 2011;58:482–90.

    Article  CAS  PubMed  Google Scholar 

  22. Marinello PC, da Silva TN, Panis C, Neves AF, Machado KL, Borges FH, Guarnier FA, Bernardes SS, de-Freitas-Junior JC, Morgado-Diaz JA, Luiz RC, Cecchini R, Cecchini AL. Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor beta1 induction. Tumour Biol. 2015.

  23. Yang X, Sun D, Tian Y, Ling S, Wang L. Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating bcl2 expression. Tumour Biol. 2015;36:2957–64.

    Article  CAS  PubMed  Google Scholar 

  24. Lee JH, Kim JH, Kim JS, Chang JW, Kim SB, Park JS, et al. AMP-activated protein kinase inhibits TGF-beta-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am J Physiol Renal Physiol. 2013;304:F686–97.

    Article  CAS  PubMed  Google Scholar 

  25. Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F, et al. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. Tumour Biol. 2015;36:9873–83.

    Article  CAS  PubMed  Google Scholar 

  26. Gou S, Cui P, Li X, Shi P, Liu T, Wang C. Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PLoS ONE. 2013;8:e63969.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003;113:643–55.

    Article  CAS  PubMed  Google Scholar 

  28. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–14.

    Article  CAS  PubMed  Google Scholar 

  29. Yin X, Zhang BH, Zheng SS, Gao DM, Qiu SJ, Wu WZ, et al. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. J Hematol Oncol. 2015;8:23.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sid B, Glorieux C, Valenzuela M, Rommelaere G, Najimi M, Dejeans N, et al. AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells. Biochem Pharmacol. 2014;91:168–80.

    Article  CAS  PubMed  Google Scholar 

  31. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev. 2006;70:1061–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Guo L, Guo Y, Xiao S, Shi X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci. 2005;77:1869–78.

    Article  CAS  PubMed  Google Scholar 

  33. Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, et al. ANXA3/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem Cell Rep. 2015;5:45–59.

    Article  CAS  Google Scholar 

  34. Brill LM, Xiong W, Lee KB, Ficarro SB, Crain A, Xu Y, et al. Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell. 2009;5:204–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Dai RY, Zhao XF, Li JJ, Chen R, Luo ZL, Yu LX, et al. Implication of transcriptional repression in compound C-induced apoptosis in cancer cells. Cell Death Dis. 2013;4:e883.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Liu X, Chhipa RR, Nakano I, Dasgupta B. The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther. 2014;13:596–605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by research funds from the Biomedical Research Institute of Chonbuk National University Hospital.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, South Korea

    Chen Shen, Su Jin Kim & Ji Hyun Park

  2. Department of Biochemistry, Chonbuk National University Medical School, Jeonju, South Korea

    Sun-O Ka & Byung-Hyun Park

  3. Division of Endocrinology and Metabolism, Department of Internal Medicine, Presbyterian Medical Center, Jeonju, South Korea

    Ji Hye Kim

  4. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonbuk National University Medical School, 20 Geonji-ro, Deokjin-gu, Jeonju, 54907, South Korea

    Ji Hyun Park

Authors
  1. Chen Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sun-O Ka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Su Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ji Hye Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Byung-Hyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ji Hyun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ji Hyun Park.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shen, C., Ka, SO., Kim, S.J. et al. Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK. Tumor Biol. 37, 11199–11208 (2016). https://doi.org/10.1007/s13277-016-5007-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5007-0

Keywords

Search

Navigation